• Home
  • NEW DAY MEDICINE
  • 2 (34) 2021
  • 65 -2 (34) 2021 — Niyozov G.E., Oblokulov A.R., — IMPORTANCE OF IDENTIFYING MARKERS OF COAGULOPATHY IN COVID-19 PATIENTS

65 -2 (34) 2021 — Niyozov G.E., Oblokulov A.R., — IMPORTANCE OF IDENTIFYING MARKERS OF COAGULOPATHY IN COVID-19 PATIENTS

IMPORTANCE OF IDENTIFYING MARKERS OF COAGULOPATHY IN COVID-19 PATIENTS

Niyozov G.E., Bukhara state medical Institute named after Abu Ali Ibn Sino

Oblokulov A.R., Bukhara state medical Institute named after Abu Ali Ibn Sino

Jalilova A.S. Bukhara state medical Institute named after Abu Ali Ibn Sino

Resume

The value of D-dimer (DD), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FG) coagulation parameters in predicting the severity and prognosis of COVID-19 was studied. Violation of blood clotting function was found in almost all, more often in old patients.

Indicators of hemostatic homeostasis such as D-dimer, prothrombin time  and  fibrinogen   can be used as indicators of the severity of the disease in patients.

Keywords: COVID-19, coagulation, prothrombin time, fibrin breakdown products, D-dimer, prognosis.

First page

332

Last page

336

For citation: Niyozov G.E., Oblokulov A.R., Jalilova A.S. Importance of identifying markers of coagulopathy in covid-19 patients //New Day in Medicine 2(34)2021 332-336 https://cutt.ly/OnOYYKc

LIST OF REFERENCES

  1. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed: 31 may 2020.
  2. Oblokulov A.R., Musaeva D.M., Elmuradova A.A. (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). // New Day in Medicine. №2 (30/2) p.110-115.
  3. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. JACC. 2020. doi:10.1016/j.jacc.2020.04.031.
  4. Cao Y., Liu X., Xiong L. et al.  Imaging and clinical features of patients with 2019 novel coronavirus SARS‑CoV‑2: a systematic review and meta‑analysis. J. Med. Virol., 2020; doi: 10.1002/jmv.25 822.
  5. Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, Volume 25: Issue 3. 5220–5224.
  6. Iba T., Levy J.H., Levi M. и соавт.: Coagulopathy of coronavirus disease 2019. Crit. Care Med., 2020; doi: 10.1097/CCM.0 000 000 000 004 458].
  7. Levi M., Thachil J., Iba T., Levye J.H.: Coagulation abnormalities and thrombosis in patients with COVID‑19. Lancet Haematol. 2020; 7: e438–e440].
  8. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. 
  9. Chen N, Zhou M, Dong X.  et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.2020;395:507-513.
  10. Han H, Yang L, Liu R et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med.2020;58:1116-1120.
  11. Tao J, Song Z, Yang L. et al. Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department. Br J Dermatol. 2020;182:1477-1478.
  12. Wang L, He WB, Yu XM. et al. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients. World J Clin Cases 2020; 8(19): 4370-4379.
  13. Oblokulov, A. R., Niyozov, G.E. (2020) Clinical and epidemiological characteristics of patients with COVID-19 International Journal of Pharmaceutical Research; 12(4):3749-3752.
  14. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844–847.
  15. Huan H., Lan Y., Liu R., et al. Prominent changes in blood coagulation of patients with SARS-Cov2 infection. Clin Chem Lab Med. 2020; 58(7): 1116–1120. DOI: 10/1515/cclm-2020-0188.
  16. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.
  17. Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020; 382 (18): 1708–1720. DOI: 10.1056/NEJMoa2002032.
  18. Yin S., Huang M., Li D., Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J. Thromb. Thrombolysis. [Preprint. Posted: 2020, Apr. 3].

file

download